Pharmacotherapy of cough-variant asthma.

abstract：:Maximal surgical debulking and radiotherapy have been the cornerstone of therapy for high-grade gliomas. The impact of chemotherapy on outcome has been marginal and, until recently, its usage has been debatable. The development of new drugs and an improved understanding of chemoresistance have reinvigorated interest i...

journal_title：Expert opinion on pharmacotherapy

authors： Cavaliere R,Newton H

更新日期：2006-04-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

journal_title：Expert opinion on pharmacotherapy

authors： Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

更新日期：2013-10-01 00:00:00

abstract：:The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical ef...

journal_title：Expert opinion on pharmacotherapy

authors： Kwon DS,Mylonakis E

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

journal_title：Expert opinion on pharmacotherapy

authors： Brook I

更新日期：2011-08-01 00:00:00

abstract：:Negative symptoms are core features of schizophrenia that respond poorly to first-generation antipsychotics and present a major obstacle in rehabilitation. Patients may be somewhat more responsive to clozapine and second-generation antipsychotics but even then, considerable impairment remains. This paper reviews the u...

journal_title：Expert opinion on pharmacotherapy

authors： Silver H

更新日期：2004-10-01 00:00:00

abstract：INTRODUCTION:Metastatic prostate cancer is an incurable disease that is treated with a variety of hormonal therapies targeting various nodes of the androgen receptor (AR) pathway. Invariably patients develop resistance and become castration resistant. Common treatments for castration-resistant disease include novel hor...

journal_title：Expert opinion on pharmacotherapy

authors： Maughan BL,Antonarakis ES

更新日期：2015-01-01 00:00:00

abstract：:Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory condition that is associated with progressive joint destruction and reduced quality of life. Despite the common use of disease-modifying anti-rheumatic drugs (DMARDs) in PsA, their influence has been investigated in a number of studies with conflicting ...

journal_title：Expert opinion on pharmacotherapy

authors： Abdulrahim H,Sharlala H,Adebajo AO

更新日期：2019-11-01 00:00:00

abstract：INTRODUCTION:Ceftazidime is a third-generation cephalosporin that has activity against Gram-negative bacilli, including Pseudomonas aeruginosa. The increasing prevalence of antimicrobial resistance and the limited number of antimicrobial agents in development have necessitated a review of the current status of treatmen...

journal_title：Expert opinion on pharmacotherapy

authors： Choi SH,Koh Y

更新日期：2012-10-01 00:00:00

abstract：INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

journal_title：Expert opinion on pharmacotherapy

authors： Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

更新日期：2021-01-01 00:00:00

abstract：:The treatment of acute decompensated heart failure (ADHF) remains a therapeutic challenge. Nesiritide was approved by the FDA in 2001 for the treatment of patients with ADHF who have dyspnea at rest or with minimal exertion. Although widely adopted for the treatment of ADHF due to its ability to decrease ventricular f...

journal_title：Expert opinion on pharmacotherapy

authors： Shah SJ,Teerlink JR

更新日期：2007-02-01 00:00:00

abstract：:Shock associated with systemic inflammatory response syndrome (SIRS) is a form of distributive shock affecting over 200,000 patients per year in the US that results in 50% mortality. The role of NO in a variety of shock states has been extensively studied and has been shown to be the primary effector in endotoxin lipo...

journal_title：Expert opinion on pharmacotherapy

authors： De Angelo J

更新日期：1999-11-01 00:00:00

abstract：:Introduction: This clinical guidance looks at the specific concerns of delivery of medical treatment for people with epilepsy and intellectual disability (ID). People with ID have not been included in licensing drug trials of AEDs. However, this population has an over-representation of seizure comorbidity, treatment r...

journal_title：Expert opinion on pharmacotherapy

authors： Watkins L,O'Dwyer M,Kerr M,Scheepers M,Courtenay K,Shankar R

更新日期：2020-02-01 00:00:00

abstract：:Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

journal_title：Expert opinion on pharmacotherapy

authors： El-Sakka AI,Shamloul R,Yassin AA

更新日期：2009-09-01 00:00:00

abstract：INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

journal_title：Expert opinion on pharmacotherapy

authors： Yamaoka K,Tanaka Y

更新日期：2014-01-01 00:00:00

abstract：INTRODUCTION:Kidney transplantation is the treatment of choice for patients with end-stage renal failure, and their survival after transplantation is gradually improving. Everolimus (EVL) is a mammalian target of rapamycin inhibitor, providing a safe and effective immunosuppressive regime after kidney transplantation. ...

journal_title：Expert opinion on pharmacotherapy

authors： Dantal J

更新日期：2012-04-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Hypertension is a major independent risk factor for kidney disease and for faster renal function loss. Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD). AREAS COVERED IN THIS REVIEW:The pres...

journal_title：Expert opinion on pharmacotherapy

authors： Cravedi P,Ruggenenti P,Remuzzi G

更新日期：2010-11-01 00:00:00

abstract：INTRODUCTION:Breast cancer is a common, life-threatening disease among women. Contemporary hormonal therapy with third-generation aromatase inhibitors for estrogen-receptor-positive breast cancers in postmenopausal women is still facing the challenge of interpatient variability in therapeutic response and intensity of ...

journal_title：Expert opinion on pharmacotherapy

authors： Turkistani A,Marsh S

更新日期：2012-06-01 00:00:00

abstract：INTRODUCTION:Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases o...

journal_title：Expert opinion on pharmacotherapy

authors： Janicak PG,Rado JT

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Antipsychotic drugs are increasingly used in the maintenance treatment of bipolar disorder. This review addresses the evidence supporting the use of one of these medications for this indication in order to place available data in perspective for the clinician. AREAS COVERED:The approval of ziprasidone for...

journal_title：Expert opinion on pharmacotherapy

authors： Dubovsky SL,Dubovsky AN

更新日期：2011-04-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a rare disease characterized by the accumulation of clonal dendritic cells in different organs. Most recent findings (e.g., activating BRAF mutations) favor the hypothesis that LCH may represent a neoplasm with varying behavior, but the ultimate pathogenesis remains to be uncover...

journal_title：Expert opinion on pharmacotherapy

authors： Minkov M

更新日期：2012-08-01 00:00:00

abstract：INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

journal_title：Expert opinion on pharmacotherapy

authors： Bernstein JA

更新日期：2013-10-01 00:00:00

abstract：INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

journal_title：Expert opinion on pharmacotherapy

authors： Passero FC Jr,Saif MW

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Despite its frequency, recognition and therapy of vulvovaginal atrophy (VVA) remain suboptimal. Wet mount microscopy, or vaginal pH as a proxy, allows VVA diagnosis in menopause, but also in young contraception users, after breast cancer, or postpartum. Intravaginal low dose estrogen product is the main th...

journal_title：Expert opinion on pharmacotherapy

authors： Donders GGG,Ruban K,Bellen G,Grinceviciene S

更新日期：2019-05-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Currently available small case reports clearly propose that existing regulatory procedures to approve generic versions only require essential bioequivalence, have limitations and fail to meet stricter scientific and clinical demands. AREAS COVERED IN THIS REVIEW:Data indicate that paroxetine me...

journal_title：Expert opinion on pharmacotherapy

authors： Pae CU,Misra A,Ham BJ,Han C,Patkar AA,Masand PS

更新日期：2010-02-01 00:00:00

abstract：:The prevalence of obesity has noticeably increased worldwide. The clinician is now frequently facing the challenge of managing patients with concomitant chronic obstructive pulmonary disease (COPD) or asthma and obesity. Obesity is often associated with a poorer control of these chronic respiratory diseases and the op...

journal_title：Expert opinion on pharmacotherapy

authors： Lessard A,Maltais F,Boulet LP

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:The introduction of novel agents has significantly improved multiple myeloma (MM) patient outcome during the last two decades. MM received the most drug approvals for any one malignancy during this time period, both in the United States as well as in Europe. Areas covered: Proteasome inhibitors, immunomodu...

journal_title：Expert opinion on pharmacotherapy

authors： Podar K,Pecherstorfer M

更新日期：2017-08-01 00:00:00

abstract：:Bupropion, a noradrenaline and dopamine re-uptake inhibitor, has long been indicated for the treatment of depression. Recent studies have demonstrated additional benefits in depression, including: prevention of the recurrence of seasonal affective disorder in depressive subtypes with decreased energy, pleasure and int...

journal_title：Expert opinion on pharmacotherapy

authors： Clayton AH

更新日期：2007-03-01 00:00:00

abstract：INTRODUCTION:Glioblastoma multiforme (GBM) is the most common high grade primary brain tumor in adults. Despite significant advances in treatment, the prognosis remains poor. Bevacizumab (BVZ) and irinotecan (CPT-11) are currently being investigated in the treatment of GBM patients. Although treatment with BVZ and irin...

journal_title：Expert opinion on pharmacotherapy

authors： Jakobsen JN,Hasselbalch B,Stockhausen MT,Lassen U,Poulsen HS

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. OBJECTIVE:In this articl...

journal_title：Expert opinion on pharmacotherapy

authors： Barragan P,Podzamczer D

更新日期：2008-09-01 00:00:00

abstract：:Initially it was considered that moxonidine, like clonidine, acted at central (2)-adrenoceptors to reduce blood pressure. With the characterisation of imidazoline binding sites distinct from (2)-adrenoceptors, the consensus became that moxonidine was acting predominantly at imidazoline I(1) receptors in the rostral ve...

journal_title：Expert opinion on pharmacotherapy

authors： Doggrell SA

更新日期：2001-02-01 00:00:00